Arvinas
ARVN
About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Employees: 430
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
296% more call options, than puts
Call options by funds: $26.4M | Put options by funds: $6.68M
46% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 52
33% more funds holding in top 10
Funds holding in top 10: 6 [Q1] → 8 (+2) [Q2]
14% more capital invested
Capital invested by funds: $451M [Q1] → $516M (+$64.2M) [Q2]
2.46% more ownership
Funds ownership: 93.19% [Q1] → 95.65% (+2.46%) [Q2]
2% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 52
0% more funds holding
Funds holding: 213 [Q1] → 213 (+0) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
|
Barclays
Etzer Darout
|
$16
|
Overweight
Assumed
|
17 Sep 2025 |
|
HC Wainwright & Co.
Andrew S. Fein
|
$18
|
Buy
Maintained
|
7 Aug 2025 |
|
Wells Fargo
Derek Archila
|
$16
|
Overweight
Maintained
|
7 Aug 2025 |
|
Guggenheim
Michael Schmidt
|
$15
|
Buy
Maintained
|
7 Aug 2025 |
Financial journalist opinion
Based on 4 articles about ARVN published over the past 30 days
